Other

Covalent Bioscience Incorporated

The University of Texas System

Paul, Sudhir

Nishiyama, Yasuhiro

Planque, Stephanie

Smith, Keri C.

Brown, Eric L.

Taguchi, Hiroaki

Yasuhiro Nishiyama

Sudhir Paul

Eric L Brown

Hiroaki Taguchi

Stephanie Planque

Keri C Smith

Disclosed are antibodies (immunoglobulins) and fragments thereof that hydrolyze or bind polypeptide antigens belonging to, hepatitis C virus, human immunodeficiency virus and Alzheimer's disease. Also disclosed are novel methods to improve the antigen reactivity of the immunoglobulins and to treat a pathophysiological condition using the immunoglobulins as therapeutics.

Immunoglobulins directed to bacterial, viral and endogenous polypetides

Immunoglobulins directed to bacterial, viral and endogenous polypeptides

A covalently reactive ligand analogue (CAL) of formula (1): wherein, L. . . L. . . Lare components defining a ligand determinant, Lis a component unit of the ligand determinant selected from the group consisting of an amino acid residue, sugar residue, a fatty acid residue and a nucleotide, L' is a functional group of L, Y&#x2033; is atom, covalent bond or linker, Y&#x2032; is an optional charged or neutral group Y is a covalently reactive electrophilic group that reacts specifically with a receptor that binds to said ligand determinant, and n is an integer from 1 to 1000 m is an integer from 1 to 30.

Covalent attachment of ligands to nucleophilic proteins guided by non-covalent

Improved methods for the production, selection and inhibition of catalytic and covalent antibodies are disclosed.

Proteolytic and covalent antibodies

Improved methods for the production, selection and inhibition of catalytic antibodies are disclosed.

Covalently reactive transition state analogs and methods of use thereof

Growing community of inventors

Houston, TX, United States of America

Yasuhiro Nishiyama